N/A
N=62
Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT03830359 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Ocular Symptomatology — -55.9 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- T2769 (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Laboratoires Thea
- Primary completion
- Feb 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ocular Symptomatology |
-55.9 | — |
Summary
Efficacy of T2769 in Dry Eye Desease
Eligibility Criteria
Inclusion Criteria
- Signed and dated informed consent
- Male or female aged from ≥ 18 years old
- Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study screening
Exclusion Criteria
- Best far corrected visual acuity ≤ 2/10
- Severe blepharitis Severe dry eye
Data sourced from ClinicalTrials.gov (NCT03830359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.